Monitor for FDA decision on obexelimab in IgG4-RD as commercial launch readiness improves; watch for clinical updates from orelabrutinib Phase 3 program. Note that convertible notes are not immediately dilutive but could be in the future if converted above $26.50.
Price Chart
Executive Summary
Zenas BioPharma announced a $200 million convertible notes offering and a $100 million equity offering (5 million shares at $20.00 per share), raising approximately $287.5 million in net proceeds. The funds will support the potential U.S. commercial launch of obexelimab and advance its clinical pipeline, including Phase 3 trials for orelabrutinib in progressive multiple sclerosis.
Key Financial Metrics
Key Facts
- Raised $200 million via 2.50% convertible senior notes due 2032 with a 32.5% conversion premium ($26.50/share).
- Simultaneously raised $100 million through issuance of 5 million common shares at $20.00 per share.
- Net proceeds estimated at $287.5 million after underwriting discounts and expenses.
- Use of proceeds: U.S. launch preparation for obexelimab (if approved), Phase 3 orelabrutinib trials, ZB021 development, and general corporate purposes.
- Underwriters granted 30-day options to purchase up to an additional $30 million in notes and 750,000 shares.
Financial Impact
$287.5 million in net proceeds; $100 million equity issuance implies ~5% dilution assuming 100 million shares outstanding pre-offering
Risk Factors
- Dilution risk if convertible notes are exercised, especially if stock price rises above $26.50.
- Company remains pre-revenue with substantial future losses expected; going concern uncertainty noted in prior 10-K.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263539 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Press Release | $26.71 | awaiting T+60 | — | $27.24 (+1.98%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.24 (+8.27%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.24 (−17.58%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.24 (−16.31%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.24 (−14.63%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.24 (+46.77%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.24 (+52.69%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.24 (+36.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers